Send Message
BZO Rapid Test Cassette Urine Oxazepam Major Metabolite CE / FDA

BZO Rapid Test Cassette Urine Oxazepam Major Metabolite CE / FDA

  • High Light

    BZO Rapid Test Cassette


    BZO Drug Abuse Test Kit


    FDA Drug Abuse Test Kit

  • Product
    BZO Rapid Test Cassette (Urine), Oxazepam (major Metabolite), Drug Of Abuse,CE/FDA
  • Cat No.
  • Principle
    Chromatographic Immunoassay
  • Format
    Urine,Oral Fluid,Powder,WB/S/P,Hair
  • Specimen
  • Certificate
  • Reading Time
    5 Minutes
  • Pack
  • Sensitivity
  • Specificity
  • Accuracy
  • Cut-Off
    100 Ng/mL, 200 Ng/mL, 300 Ng/mL*,20 Ng/mL ,30 Ng/mL*, 50 Ng/mL ,0.2 Ng/mg
  • Place of Origin
  • Brand Name
  • Certification
  • Model Number
  • Minimum Order Quantity
  • Price
  • Packaging Details
  • Delivery Time
    2-4 Weeks

BZO Rapid Test Cassette Urine Oxazepam Major Metabolite CE / FDA


BZO Rapid Test Cassette (Urine), Oxazepam (major metabolite), drug of abuse,CE/FDA


Principle Chromatographic Immunoassay
Format Dipstick, Cassette, Panel, Device, Cup
Specimen Urine,Oral Fluid,Powder,WB/S/P,Hair
Certificate CE/FDA
Reading Time 5 minutes
Pack 10T/25T/40T/50T
Storage Temperature 2-30°C
Shelf Life 2 Years
Sensitivity 98.20%
Specificity 97.80%
Accuracy 98.00%
Cut-Off 100 ng/mL, 200 ng/mL, 300 ng/mL*,20 ng/mL ,30 ng/mL*, 50 ng/mL ,0.2 ng/mg




  • Fast results
  • Easy visually interpretation
  • Simple operation, no equipment required
  • High accuracy


A rapid test for the qualitative detection of Benzodiazepines in human urine. For medical and other professional in vitro diagnostic use only
The BZO Rapid Test Cassette (Urine) is a rapid chromatographic immunoassay for the detection of Oxazepam (major metabolite) in urine at a cut-off concentration of 100ng/ml. This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert. 
This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced Barbiturates in the treatment of both anxiety and insomnia.
Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception. Only trace amounts (less than 1%) of most Benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug.
The detection period for the Benzodiazepines in the urine is 3-7 days. The BZO Rapid Test Cassette (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes the antibody to selectively detect elevated levels of Benzodiazepines in urine. The BZO Rapid Test Cassette (Urine) yields a positive result when the Benzodiazepines in urine exceeds the cut-off level.
The BZO Rapid Test Cassette (Urine) is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody. During testing, a urine specimen migrates upward by capillary action. Benzodiazepines, if present in the urine specimen below the cut-off level, will not saturate the binding sites of the antibody in the test.
The antibody coated particles will then be captured by immobilized Benzodiazepines-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Benzodiazepines level exceeds the cut-off level, because it will saturate all the binding sites of anti-Benzodiazepines antibody.
A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.
The test contains mouse monoclonal anti-Benzodiazepines antibody coupled particles and Benzodiazepines-protein conjugate. A goat antibody is employed in the control line system.
Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.
Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.
1. Bring the pouch to room temperature before opening it. Remove the test cassette from the sealed pouch and use it within one hour.
2. Place the test device on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine (approx. 120 uL) to the specimen well (S) of the test cassette, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration below.
3. Wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes.
BZO Rapid Test Cassette Urine Oxazepam Major Metabolite CE / FDA 0
(Please refer to the illustration above)
NEGATIVE:* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Benzodiazepine concentration is below the detectable cut-off level.
*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.
POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the Benzodiazepine concentration exceeds the detectable cut-off level.
INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.
Order Information
Cat. No. Product Specimen Pack
DBZ-102 Benzodiazepines (BZO) Rapid Test Cassette Urine 40T
DBZ-114 Benzodiazepines (BZO) Rapid Test Panel Urine 40 T
DBZ-802 Benzodiazepines (BZO) Rapid Test Cassette Oral Fluid 25 T
DBZ-803 Benzodiazepines (BZO) Rapid Test Device Oral Fluid 25 T
DBZ-402 Benzodiazepines (BZO) Rapid Test Cassette WB/S/P 40 T
DBZ-X14 Benzodiazepines (BZO) Rapid Test Panel Powder 25 T
DBZ-H902 Benzodiazepines (BZO) Rapid Test Cassette Hair 10 T
A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.
Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper test performance.